biostudies-literatureUnknown12(10)Wang MM<h4>Background</h4>Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>) mutation seemingly suffered less effective therapeutic regimens in the absence of widely-accepted targeted drugs compared with other mutation types in non-small cell lung cancer (NSCLC). However, whether these non-selective therapy schedules for <i>KRAS</i> mutation matters is still under debate. Correspondingly, we aimed to compare the long term expectancy of indicated therapeutic regimes and further explore the optimal schemes of <i>KRAS</i> mutated NSCLC in the absence of targeted drugs in this retrospective study cohort.<h4>Methods</h4>We conducted a single-center retrospective analysis among 66 patients diagnosed with <i>KRAS</i>-mutant advanced NSCLC from November 2018 to December 2020. These enrolled cases wTranslational lung cancer research2030-2039https://www.ebi.ac.uk/biostudies/studies/S-EPMC10654440biostudies-literatureClinical outcomes of <i>KRAS</i>-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study.PMC10654440Shan HLZhang YWu SQu SYYang XMWang MMXu XSong LQZhang SYfalseClinical outcomes of <i>KRAS</i>-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study.<h4>Background</h4>Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>) mutation seemingly suffered less effective therapeutic regimens in the absence of widely-accepted targeted drugs compared with other mutation types in non-small cell lung cancer (NSCLC). However, whether these non-selective therapy schedules for <i>KRAS</i> mutation matters is still under debate. Correspondingly, we aimed to compare the long term expectancy of indicated therapeutic regimes and further explore the optimal schemes of <i>KRAS</i> mutated NSCLC in the absence of targeted drugs in this retrospective study cohort.<h4>Methods</h4>We conducted a single-center retrospective analysis among 66 patients diagnosed with <i>KRAS</i>-mutant advanced NSCLC from November 2018 to December 2020. These enrolled cases w2023-01-01T00:00:00Z2023 Oct2026-06-03T09:46:25.308Z2025-04-05T10:23:25.872ZS-EPMC106544403802581710.21037/tlcr-23-449